Novo seeks FDA nod for next-gen weight loss drug (NVO:NYSE)

Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine

Here’s how the next generation of obesity drugs getting closer to patients differs from Wegovy and Zepbound Article Attribution | Read More at Article Source The post Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine appeared first on RocketNews.

Novo seeks FDA nod for next-gen weight loss drug (NVO:NYSE)

Novo Nordisk (NVO) stock gains as the company files for FDA approval of CagriSema, its next-gen obesity drug which causes up to 23% weight reduction. Read more here.

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition.CagriSema is a fixed-dose combination of a long-acting a…

Novo Nordisk files FDA application for once-weekly obesity treatment

PLAINSBORO, N.J. — Novo Nordisk has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for CagriSema, a once-weekly injectable combination therapy for chronic weight management that pairs a GLP-1 receptor agonist with an amylin analogue.If approved, CagriSema would become the first fixed-dose injectable combination of semaglutide and the novel amylin analogue cagrilintide. The therapy is designed for use a…